CompletedPhase 1NCT01606878
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Emily Greengard, M.DCOG Phase I Consortium
- Intervention
- Crizotinib(drug)
- Enrollment
- 46 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2013 – 2018
Study locations (23)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- C S Mott Children's Hospital, Ann Arbor, Michigan, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University/Herbert Irving Cancer Center, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01606878 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation